The average one-year price target for Beam Therapeutics (BMV:BEAM) has been revised to MX$839.72 / share. This is a decrease of 13.38% from the prior estimate of MX$969.43 dated September 13, 2026.
Fintel on MSN
Citigroup downgrades Moderna to sell from neutral
Fintel reports that on 30 September 2026, Citigroup downgraded their outlook for Moderna (SWX:MRNA) from Neutral to Sell. This rating action follows a prior action on 3 August 2026, when Citigroup ...
NEET UG 2026 paper leak CBI investigation latest update and final chargesheet details. Follow Dainik Bhaskar. NEET-UG 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results